Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care therapies, announced today the U.S. launch of CAMCEVI™ (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults. Accord BioPharma is heading distribution in the U.S. The U.S. Food and Drug Administration approved…

eTurboNews tala e mo na'o le au fai saofaga. O le lesitala o saʻoloto.
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE

OA MEA E AVEA MAI LENEI TUSI:

focused on development of oncology, immunology, and critical care therapies, announced today the U.
Accord BioPharma is heading distribution in the U.
launch of CAMCEVI™ (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.